All Stories
- Nephrology Clinical Trials in Learning Health Systems
Article
- Decreasing Bladder Cancer Survival: Insights from a Population-Based Registry
Article
- Testicular Metastasis: Origin, Outcome and Prognosis
Article
- The importance of transparency in the conduct of biomarker research
Article
- How circular designs of buildings can reduce carbon emissions
Article
- Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People with Rheumatic Diseases
Article
- Impact of Ozempic and Similar Medications on Facial Appearance
Article
- Semaglutide: A Diabetes Medication with Expanding Applications
Article
- OZEMPIC NO TRATAMENTO DA OBESIDADE E RISCOS ASSOCIADOS AO USO INDISCRIMINADO
Article
- More people Googling Ozempic for weight loss
Article
- Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective
- Using Ozempic for Weight Loss Beyond Diabetes Treatment
Article
- Concerns About 'Ozempic Face' Phenomenon
Article
- Decade-long trends in prostate cancer biopsy and treatment within a population-based registry
- Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV): protocol and cohort profile
Article
- Eating better, living healthier: Simple changes for type 2 diabetes management
Article
- ANÁLISE DO INDISCRIMINADO USO OFF LABEL DE OZEMPIC PARA EMAGRECIMENTO
- Biodiversity: Understanding, Valuing, and Addressing Decline
Article
- Semaglutide (Ozempic) for Obesity: Pros and Cons
Article
- Hooker's Willow - history, description and illustration
Article
- Integrating Sustainability into Healthcare Research: Why Research Should Care
Article
- A new way to measure inclusive development
Article
- A atuação do farmacêutico no uso da semaglutida (Ozempic): uma revisão integrativa / The performance of the pharmacist in the use of semaglutida (Ozempic): an integrative review
- Semaglutide for Obesity Treatment: Efficacy and Safety
Article
- Using Semaglutide (Ozempic) in Real Clinical Practice
Article
- Ozempic: Diabetes Medication, Benefits, and Risks
Article
- Human medicines European public assessment report (EPAR): Ozempic, semaglutide, Diabetes Mellitus, Date of authorisation: 08/02/2018, Revision: 2, Status: Authorised
- What is involved in taking a journal from issue-by-issue publication to continuous publication?
Article
- Authors want to promote work via PDF sharing sites without contravening copyright
Article
- Semaglutide Reduces Cardiovascular Risk in Type 2 Diabetes
Article
- Prey enbalming hinders chemical diversity in digger wasps
- Load balanced transaction scheduling using Honey Bee Optimization considering performability
Article
- Does sharing on Social Media help the visibility of research?
- Tips for effective use of social media to promote scholarly publications
Article
- How Kudos can help you increase readership and broaden the context of your work
Article
- Introducing our Editorial Board
- Getting mobile right: start with who and why, not what and how
- Integrating social media marketing in the marketing mix.
Article
- Business and technical decisions around mobile product development
- This is a summary of my research.
Article
- Tiered pricing for scholarly publishers
- Online. Indexed. Catalogued. Free. But will users find it?
- IESR: a new database to encourage use of e-resources
- Knowledge bases: improving the information supply chain
- Social networking for scholarly use - a view from 2007
- A brief history of linking technology in scholarly publishing